|
|
||||||||
Faculty of Pharmaceutical Sciences and Faculty of Medicine, Kyoto University, Kyoto, Japan
Correspondence: For correspondence and reprints contact: Akira Yokoyama, PhD, Dept. of Radiopharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606 Japan.
ABSTRACT
To achieve high and selective target radioactivity localization by monoclonal antibodies (Mabs) labeled with metallic radionuclides, the discriminated release of a hippurate-like radiometal chelate in nontarget tissues was performed using chemically modified Mabs. Methods: The disulfide bonds of a Mab against osteogenic sarcoma (OST7, IgG1) were reduced and 67Ga chelate of succinyldeferoxamine (SDF) was conjugated proximal to the Mab molecule via an ester bond with exposed thiol groups (67Ga-DFO-MESS-redOST7), which would impair esterase access to the ester bond of 67Ga-DFO-MESS-redOST7 due to the steric interference induced by bulky antibody molecule, stabilizing the ester bond in plasma and on the target cell's surface. Gallium-67-SDF was also conjugated to OST7 via an ester bond with 2-iminothiolane to render the ester bond in a position distal from the OST7 molecule (67Ga-DFO-MESS-IT-OST7). Results: Although SDS-PAGE analyses of 67Ga-DFO-MESS-redOST7 showed a partial cleavage of its disulfide bonds, size-exclusion HPLC and cell binding assays indicated that the IgG structure and immunoreactivity of this conjugate were preserved in a neutral buffer and plasma of the systemic circulation. Conclusion: The present radiochemical design of an antibody utilizing pH-dependent dissociation would constitute a promising approach in establishing selective target radioactivity localization by Mabs.
Key Words: gallium-67 monoclonal antibodies target selection
This article has been cited by other articles:
![]() |
I. Verel, G. W.M. Visser, R. Boellaard, M. Stigter-van Walsum, G. B. Snow, and G. A.M.S van Dongen 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies J. Nucl. Med., August 1, 2003; 44(8): 1271 - 1281. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |